TY - JOUR
T1 - Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
AU - Yamada, Shinji
AU - Itai, Shunsuke
AU - Kaneko, Mika K.
AU - Kato, Yukinari
N1 - Funding Information:
This research was supported in part by AMED under Grant numbers: JP17am0301010 (Y.K.), JP17am0101078 (Y.K.), and JP17ae0101028 (Y.K.), and by JSPS KAKENHI Grant number 17K07299 (M.K.K.) and Grant number 16K10748 (Y.K.).
Publisher Copyright:
© 2018 The Authors
PY - 2018/3
Y1 - 2018/3
N2 - Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), L1Mab-4 (IgG2b, kappa), using cell-based immunization and screening (CBIS) method and investigated hPD-L1 expression in oral cancers. L1Mab-4 reacted with oral cancer cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-3, and HSC-4) in flow cytometry and stained oral cancers in a membrane-staining pattern. L1Mab-4 stained 106/150 (70.7%) of oral squamous cell carcinomas, indicating the very high sensitivity of L1Mab-4. These results indicate that L1Mab-4 could be useful for investigating the function of hPD-L1 in oral cancers.
AB - Programmed cell death-ligand 1 (PD-L1), which is a ligand of programmed cell death-1 (PD-1), is a type I transmembrane glycoprotein that is expressed on antigen-presenting cells and several tumor cells, including melanoma and lung cancer cells. There is a strong correlation between human PD-L1 (hPD-L1) expression on tumor cells and negative prognosis in cancer patients. In this study, we produced a novel anti-hPD-L1 monoclonal antibody (mAb), L1Mab-4 (IgG2b, kappa), using cell-based immunization and screening (CBIS) method and investigated hPD-L1 expression in oral cancers. L1Mab-4 reacted with oral cancer cell lines (Ca9-22, HO-1-u-1, SAS, HSC-2, HSC-3, and HSC-4) in flow cytometry and stained oral cancers in a membrane-staining pattern. L1Mab-4 stained 106/150 (70.7%) of oral squamous cell carcinomas, indicating the very high sensitivity of L1Mab-4. These results indicate that L1Mab-4 could be useful for investigating the function of hPD-L1 in oral cancers.
KW - Monoclonal antibody
KW - Oral cancer
KW - Programmed cell death-ligand 1
UR - http://www.scopus.com/inward/record.url?scp=85041605647&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041605647&partnerID=8YFLogxK
U2 - 10.1016/j.bbrep.2018.01.009
DO - 10.1016/j.bbrep.2018.01.009
M3 - Article
AN - SCOPUS:85041605647
SN - 2405-5808
VL - 13
SP - 123
EP - 128
JO - Biochemistry and Biophysics Reports
JF - Biochemistry and Biophysics Reports
ER -
